menu
    • menu
    [{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Techdow USA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Techdow USA \/ Techdow USA","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Techdow USA"}]

    Find Clinical Drug Pipeline Developments & Deals by Techdow USA

    Menu

    Techdow USA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosaprepitant

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Techdow USA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection

                            Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.

                            Product Name : Emend-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 22, 2023

                            Lead Product(s) : Fosaprepitant

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Techdow USA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Techdow USA Announces Launch of its Generic Lovenox, (Enoxaparin Sodium – Preservative Free) in Prefilled Sy...

                            Details : Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.

                            Product Name : Lovenox-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Techdow USA

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefille...

                            Details : Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.

                            Product Name : Lovenox-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth